

## Receipt of R&D Tax Incentive payment

Antisense Therapeutics Limited ("ANP" or "the Company") would like to advise that the Company has received from the Australian Taxation Office an R&D Tax Incentive refund payment of \$284,900 in relation to expenditure incurred on eligible R&D activities for the 30 June 2018 financial year. A higher amount is anticipated for the following year in line with the greater R&D spend associated with the ongoing clinical trial of ATL1102 in DMD.

**Contact Information:** Antisense Therapeutics Limited  
Website: <https://www.antisense.com.au/>  
Managing Director: Mark Diamond +61 (0)3 9827 8999

**About Antisense Therapeutics Limited** (ASX: ANP) is an Australian publicly listed biopharmaceutical company, developing and commercialising antisense pharmaceuticals for large unmet markets. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ:IONS), world leaders in antisense drug development and commercialisation. ATL1102 (injection) has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). ATL1103 drug designed to block GHr production successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly. The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients at the Royal Childrens Hospital, Melbourne.